- Bristol-Myers Squibb Company (NYSE:BMY) and privately held PsiOxus Therapeutics (PsiOxus) announce an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with BMY's Opdivo (nivolumab), to treat a range of tumor types in late-stage cancer patients.
- Enadenotucirev is designed to have immune stimulating effects while Opdivo is designed to alleviate immune suppression. The clinical collaboration will support Phase 1 studies to determine whether combining these two agents can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses.
- Under the terms of this agreement, BMY will make a one-time upfront payment of $10M to PsiOxus, and the parties will share development costs. PsiOxus will be responsible for conducting the Phase 1 study with patient recruitment expected to start in the Q3.